Mark James Litton sold $28k of LONA
PRESIDENT and CEO at Athira Pharma, Inc.. 5,156 shares at an average of $5.37, traded Mar 4, 2026, filed Mar 5, 2026.
Score components
- +25RoleCEO
- +5Trade size$28k at market
- 0Share of holdings soldSold 8.2% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +111.4%, 3m +60.3%, 6m +43.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001604834-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2026 | MOption exercise Common Stock | +22,254 | $0.00 | $0 | 63,082 | Mar 5, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock | -5,156 | $5.37 | $28k | 57,926 | Mar 5, 2026 |
| Mar 3, 2026 | MOption exercise Restricted Stock Unitsderivative | -22,254 | $0.00 | $0 | 0 | Mar 5, 2026 |
Related signals
Other insiders at Athira Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Athira Pharma, Inc. | Church Kevin CHIEF SCIENTIFIC OFFICER | $7,298 1,359 shares | -5% | |
| 15Weak | Athira Pharma, Inc. | Martin Javier San CHIEF MEDICAL OFFICER | $9,236 1,720 shares | -10% | |
| 15Weak | Athira Pharma, Inc. | Mark Worthington GENERAL COUNSEL and CCO | $7,131 1,328 shares | -7% | |
| 22Weak | Athira Pharma, Inc. | Robert Renninger CHIEF FINANCIAL OFFICER | $4,865 906 shares | -5% | |
| 25Weak | Athira Pharma, Inc. | Mark James Litton President and CEO | $18k 2,586 shares | -6% | |
| 20Weak | Athira Pharma, Inc. | Martin Javier San CHIEF MEDICAL OFFICER | $11k 1,644 shares | -14% | |
| 15Weak | Athira Pharma, Inc. | Church Kevin CHIEF SCIENTIFIC OFFICER | $6,027 876 shares | -4% | |
| 15Weak | Athira Pharma, Inc. | Mark Worthington General Counsel and CCO | $6,027 876 shares | -6% | |
| 22Weak | Athira Pharma, Inc. | Robert Renninger Chief Financial Officer | $2,043 297 shares | -2% | |
| 15Weak | Athira Pharma, Inc. | Robert Renninger SVP, Finance and Accounting | $850 2,897 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.